Review



lonp1 selective inhibitor  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress lonp1 selective inhibitor
    ( A ) Heatmap visualization of z -scores of amino acids detected in metabolomic analysis of uninfected or EBV-infected 4 DPI B cells, treated with DMSO and 2 μM AD. ( B ) FACS CFSE analysis of newly EBV-infected primary human B cells, treated with DMSO or 100 μM AOA for 5 days. All blots are representative of n = 3 replicates. ( C ) Immunoblot analysis for V5-tagged proteins and actin in WCL of Cas9 + GM12878 LCL expressing GFP or SLC1A3. ( D ) Percentage of live cell number of GM12878 LCL expressing GFP or SLC1A3, treated with DMSO or 1 μM AD or 1 μM AD + 1 mM Asp for 48 hours. ( E ) U- 13 C-glutamine tracing schematic showing B cells at 4 DPI treated with DMSO or 2 μM AD, with malate( m + 3) measuring reductive carboxylation and malate( m + 4) measuring glutamine oxidation. ( F ) Stacked bar charts of 13 C-glutamine–labeled malate or aspartate. ( G ) Fraction of m + 4 or m + 3 malate or Asp in DMSO- or AD-treated cells at 4 DPI. ( H ) Immunoblot analysis for GOT1, GOT2, TOMM20, and actin in WCL of indicated LCLs expressing control or PTPMT1 sgRNAs. ( I ) qRT-PCR analysis of <t>LONP1</t> mRNA levels (relative to ACTB ) in indicated LCLs expressing control or PTPMT1 sgRNAs. ( J ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 treated with DMSO or 0.5 μM LONP1-in-2 for indicated time. ( K ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 LCL expressing control or PTPMT1 sgRNAs, treated with DMSO or 0.5 μM LONP1-in-2 for 24 hours. Means ± SD values in (D) and (G) ( n = 3 experiments) were analyzed using one-way ANOVA with Tukey’s test. (F) ( n = 3 experiments) used two-way ANOVA with Bonferroni’s test. (I) ( n = 3 experiments) used Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. All blots were representative of n = 3 experiments.
    Lonp1 Selective Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lonp1 selective inhibitor/product/MedChemExpress
    Average 94 stars, based on 2 article reviews
    lonp1 selective inhibitor - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Epstein-Barr virus–driven cardiolipin synthesis sustains metabolic remodeling during B cell transformation"

    Article Title: Epstein-Barr virus–driven cardiolipin synthesis sustains metabolic remodeling during B cell transformation

    Journal: Science Advances

    doi: 10.1126/sciadv.adr8837

    ( A ) Heatmap visualization of z -scores of amino acids detected in metabolomic analysis of uninfected or EBV-infected 4 DPI B cells, treated with DMSO and 2 μM AD. ( B ) FACS CFSE analysis of newly EBV-infected primary human B cells, treated with DMSO or 100 μM AOA for 5 days. All blots are representative of n = 3 replicates. ( C ) Immunoblot analysis for V5-tagged proteins and actin in WCL of Cas9 + GM12878 LCL expressing GFP or SLC1A3. ( D ) Percentage of live cell number of GM12878 LCL expressing GFP or SLC1A3, treated with DMSO or 1 μM AD or 1 μM AD + 1 mM Asp for 48 hours. ( E ) U- 13 C-glutamine tracing schematic showing B cells at 4 DPI treated with DMSO or 2 μM AD, with malate( m + 3) measuring reductive carboxylation and malate( m + 4) measuring glutamine oxidation. ( F ) Stacked bar charts of 13 C-glutamine–labeled malate or aspartate. ( G ) Fraction of m + 4 or m + 3 malate or Asp in DMSO- or AD-treated cells at 4 DPI. ( H ) Immunoblot analysis for GOT1, GOT2, TOMM20, and actin in WCL of indicated LCLs expressing control or PTPMT1 sgRNAs. ( I ) qRT-PCR analysis of LONP1 mRNA levels (relative to ACTB ) in indicated LCLs expressing control or PTPMT1 sgRNAs. ( J ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 treated with DMSO or 0.5 μM LONP1-in-2 for indicated time. ( K ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 LCL expressing control or PTPMT1 sgRNAs, treated with DMSO or 0.5 μM LONP1-in-2 for 24 hours. Means ± SD values in (D) and (G) ( n = 3 experiments) were analyzed using one-way ANOVA with Tukey’s test. (F) ( n = 3 experiments) used two-way ANOVA with Bonferroni’s test. (I) ( n = 3 experiments) used Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. All blots were representative of n = 3 experiments.
    Figure Legend Snippet: ( A ) Heatmap visualization of z -scores of amino acids detected in metabolomic analysis of uninfected or EBV-infected 4 DPI B cells, treated with DMSO and 2 μM AD. ( B ) FACS CFSE analysis of newly EBV-infected primary human B cells, treated with DMSO or 100 μM AOA for 5 days. All blots are representative of n = 3 replicates. ( C ) Immunoblot analysis for V5-tagged proteins and actin in WCL of Cas9 + GM12878 LCL expressing GFP or SLC1A3. ( D ) Percentage of live cell number of GM12878 LCL expressing GFP or SLC1A3, treated with DMSO or 1 μM AD or 1 μM AD + 1 mM Asp for 48 hours. ( E ) U- 13 C-glutamine tracing schematic showing B cells at 4 DPI treated with DMSO or 2 μM AD, with malate( m + 3) measuring reductive carboxylation and malate( m + 4) measuring glutamine oxidation. ( F ) Stacked bar charts of 13 C-glutamine–labeled malate or aspartate. ( G ) Fraction of m + 4 or m + 3 malate or Asp in DMSO- or AD-treated cells at 4 DPI. ( H ) Immunoblot analysis for GOT1, GOT2, TOMM20, and actin in WCL of indicated LCLs expressing control or PTPMT1 sgRNAs. ( I ) qRT-PCR analysis of LONP1 mRNA levels (relative to ACTB ) in indicated LCLs expressing control or PTPMT1 sgRNAs. ( J ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 treated with DMSO or 0.5 μM LONP1-in-2 for indicated time. ( K ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 LCL expressing control or PTPMT1 sgRNAs, treated with DMSO or 0.5 μM LONP1-in-2 for 24 hours. Means ± SD values in (D) and (G) ( n = 3 experiments) were analyzed using one-way ANOVA with Tukey’s test. (F) ( n = 3 experiments) used two-way ANOVA with Bonferroni’s test. (I) ( n = 3 experiments) used Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. All blots were representative of n = 3 experiments.

    Techniques Used: Infection, Western Blot, Expressing, Labeling, Control, Quantitative RT-PCR



    Similar Products

    lonp1 selective inhibitor  (MedChemExpress)
    94
    MedChemExpress lonp1 selective inhibitor
    ( A ) Heatmap visualization of z -scores of amino acids detected in metabolomic analysis of uninfected or EBV-infected 4 DPI B cells, treated with DMSO and 2 μM AD. ( B ) FACS CFSE analysis of newly EBV-infected primary human B cells, treated with DMSO or 100 μM AOA for 5 days. All blots are representative of n = 3 replicates. ( C ) Immunoblot analysis for V5-tagged proteins and actin in WCL of Cas9 + GM12878 LCL expressing GFP or SLC1A3. ( D ) Percentage of live cell number of GM12878 LCL expressing GFP or SLC1A3, treated with DMSO or 1 μM AD or 1 μM AD + 1 mM Asp for 48 hours. ( E ) U- 13 C-glutamine tracing schematic showing B cells at 4 DPI treated with DMSO or 2 μM AD, with malate( m + 3) measuring reductive carboxylation and malate( m + 4) measuring glutamine oxidation. ( F ) Stacked bar charts of 13 C-glutamine–labeled malate or aspartate. ( G ) Fraction of m + 4 or m + 3 malate or Asp in DMSO- or AD-treated cells at 4 DPI. ( H ) Immunoblot analysis for GOT1, GOT2, TOMM20, and actin in WCL of indicated LCLs expressing control or PTPMT1 sgRNAs. ( I ) qRT-PCR analysis of <t>LONP1</t> mRNA levels (relative to ACTB ) in indicated LCLs expressing control or PTPMT1 sgRNAs. ( J ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 treated with DMSO or 0.5 μM LONP1-in-2 for indicated time. ( K ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 LCL expressing control or PTPMT1 sgRNAs, treated with DMSO or 0.5 μM LONP1-in-2 for 24 hours. Means ± SD values in (D) and (G) ( n = 3 experiments) were analyzed using one-way ANOVA with Tukey’s test. (F) ( n = 3 experiments) used two-way ANOVA with Bonferroni’s test. (I) ( n = 3 experiments) used Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. All blots were representative of n = 3 experiments.
    Lonp1 Selective Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lonp1 selective inhibitor/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    lonp1 selective inhibitor - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Heatmap visualization of z -scores of amino acids detected in metabolomic analysis of uninfected or EBV-infected 4 DPI B cells, treated with DMSO and 2 μM AD. ( B ) FACS CFSE analysis of newly EBV-infected primary human B cells, treated with DMSO or 100 μM AOA for 5 days. All blots are representative of n = 3 replicates. ( C ) Immunoblot analysis for V5-tagged proteins and actin in WCL of Cas9 + GM12878 LCL expressing GFP or SLC1A3. ( D ) Percentage of live cell number of GM12878 LCL expressing GFP or SLC1A3, treated with DMSO or 1 μM AD or 1 μM AD + 1 mM Asp for 48 hours. ( E ) U- 13 C-glutamine tracing schematic showing B cells at 4 DPI treated with DMSO or 2 μM AD, with malate( m + 3) measuring reductive carboxylation and malate( m + 4) measuring glutamine oxidation. ( F ) Stacked bar charts of 13 C-glutamine–labeled malate or aspartate. ( G ) Fraction of m + 4 or m + 3 malate or Asp in DMSO- or AD-treated cells at 4 DPI. ( H ) Immunoblot analysis for GOT1, GOT2, TOMM20, and actin in WCL of indicated LCLs expressing control or PTPMT1 sgRNAs. ( I ) qRT-PCR analysis of LONP1 mRNA levels (relative to ACTB ) in indicated LCLs expressing control or PTPMT1 sgRNAs. ( J ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 treated with DMSO or 0.5 μM LONP1-in-2 for indicated time. ( K ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 LCL expressing control or PTPMT1 sgRNAs, treated with DMSO or 0.5 μM LONP1-in-2 for 24 hours. Means ± SD values in (D) and (G) ( n = 3 experiments) were analyzed using one-way ANOVA with Tukey’s test. (F) ( n = 3 experiments) used two-way ANOVA with Bonferroni’s test. (I) ( n = 3 experiments) used Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. All blots were representative of n = 3 experiments.

    Journal: Science Advances

    Article Title: Epstein-Barr virus–driven cardiolipin synthesis sustains metabolic remodeling during B cell transformation

    doi: 10.1126/sciadv.adr8837

    Figure Lengend Snippet: ( A ) Heatmap visualization of z -scores of amino acids detected in metabolomic analysis of uninfected or EBV-infected 4 DPI B cells, treated with DMSO and 2 μM AD. ( B ) FACS CFSE analysis of newly EBV-infected primary human B cells, treated with DMSO or 100 μM AOA for 5 days. All blots are representative of n = 3 replicates. ( C ) Immunoblot analysis for V5-tagged proteins and actin in WCL of Cas9 + GM12878 LCL expressing GFP or SLC1A3. ( D ) Percentage of live cell number of GM12878 LCL expressing GFP or SLC1A3, treated with DMSO or 1 μM AD or 1 μM AD + 1 mM Asp for 48 hours. ( E ) U- 13 C-glutamine tracing schematic showing B cells at 4 DPI treated with DMSO or 2 μM AD, with malate( m + 3) measuring reductive carboxylation and malate( m + 4) measuring glutamine oxidation. ( F ) Stacked bar charts of 13 C-glutamine–labeled malate or aspartate. ( G ) Fraction of m + 4 or m + 3 malate or Asp in DMSO- or AD-treated cells at 4 DPI. ( H ) Immunoblot analysis for GOT1, GOT2, TOMM20, and actin in WCL of indicated LCLs expressing control or PTPMT1 sgRNAs. ( I ) qRT-PCR analysis of LONP1 mRNA levels (relative to ACTB ) in indicated LCLs expressing control or PTPMT1 sgRNAs. ( J ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 treated with DMSO or 0.5 μM LONP1-in-2 for indicated time. ( K ) Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 LCL expressing control or PTPMT1 sgRNAs, treated with DMSO or 0.5 μM LONP1-in-2 for 24 hours. Means ± SD values in (D) and (G) ( n = 3 experiments) were analyzed using one-way ANOVA with Tukey’s test. (F) ( n = 3 experiments) used two-way ANOVA with Bonferroni’s test. (I) ( n = 3 experiments) used Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. All blots were representative of n = 3 experiments.

    Article Snippet: LONP1-in-2 (HY-153034, MedChemExpress), a LONP1 selective inhibitor , was applied at a concentration of 0.5 μM for 12 hours, with DMSO used as the vehicle control.

    Techniques: Infection, Western Blot, Expressing, Labeling, Control, Quantitative RT-PCR